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Medical science is facing issues in these days to have a 
proper grip over providing adequate treatment to the 
cancerous cells and psychosis. To address this, issue use of 
nanoparticle has been introduced into medical science. 
Nanoparticles are getting conjugated with the 
chemotherapeutic drugs so that it can get administered into 
the exact location. Similarly, it will help to detect the disease 
earlier sometimes1-18. Use of nanoparticle sometimes assists 
in making the chemotherapeutic drug easily passable 
through the intercellular membrane. Therefore, the use of 
nanoparticles of size 1 to 500 nm has been seen as an 
increase nowadays.  
To solve different issues related to cancer treatment, various 
way-outs are invented. Every single way-out are designated 
in different methods of preparation of chemotherapeutic 
drugs. The administration process of those drugs is different 
depending on the type of cancers. It has been found that 
malignant brain tumors are fatal diseases among the global 
population. The diagnosis, management, and treatment of 
the disease are much tighter, so nanoparticles are mainly 
used with chemotherapeutic drugs. Apart from that, 
multidrug resistance is another reason that restricts 
chemotherapeutic drugs to work correctly. Along with this, 
lipid nanoparticles are used conjugating with T7 peptides. 
This helps the dual modulation process of Bcl-2 and Akt-1 in 
cervical and lung carcinoma19-34.  
Sometimes, the lipid nanoparticles get loaded by the 
antisense oligonucleotides that mainly get used into the 
treatments of lung cancer. In this procedure, the 
oligonucleotide G3139-GAP is synthesized by 2-O-
methylation of the nucleotide chain in its 5 and 3 number 
end. This G3139-GAP loaded with lipid nanoparticles gets 
transformed into A549 lung cancer cell which is very much 
useful for therapeutic efficacy. Doxorubicin (DOX) is another 
drug that helps to treat malignant tumor patients. DOX needs 
to get conjugated with any peptide-based ligand to get 
delivered adequately into the exact location35-51.  
It is a unique form of doxorubicin with polycoated liposome. 
Its toxicity level is opposite than the doxorubicin toxicity.  
Use of nanoparticles along with chemotherapeutic drugs for 
the treatment of brain tumor not only makes it easier for the 
medicine to pass the cellular membrane properly but also 
helps to minimize the effect of cytotoxicity that even cause 
the death of the patient. In the case of T7 peptide conjugated 
lipid nanoparticles, the antisense oligonucleotides (ASOs) 
modulates the target genes selectively. This selective 
targeting prevents mRNAs from getting transformed into the 
protein that assists to have efficiency in preclinical studies of 
the diseased part. As a result of conjugation between G3139-
GAP, lipid nanoparticles show stability in serum and colloid. 
Also, the encapsulation capacity of the LNP gets improved. 
Apart from this, the G3139-GAP- LNP conjugation inhibits 
the growth of the tumor that prolongs the survival of the 
patients. It encourages hindering the excessive spread of the 
tumor cells into the human body19,46-51.  Use of DOX for the 
treatment of malignant tumors is the most famous cancer 
treatments available in medical science. To get the readily 
accessible peptide-based ligands the use of antibodies, small 
molecules and proteins are mostly used. The primary cause 
of using those materials is the easy availability, low cost and 
efficient resistance capability of them. Apart from that, these 
ligands get conjugated readily with Doxorubicin (DOX). 
 
 
He et al                                                                                                                         Journal of Drug Delivery & Therapeutics. 2019; 9(2):406-408      
ISSN: 2250-1177                                                                                  [407]                                                                                 CODEN (USA): JDDTAO 
 
Figure 1: Pegylated Liposomal Doxorubicin (DOX)4 
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